Study proves the effectiveness of Parkinson’s drug apomorphine

Results from the 12-week TOLEDO study – which tested the effectiveness of APO-go®/MOVAPO® (apomorphine) on Parkinson’s patients whose symptoms could not be controlled with standard therapies – showed that patients treated with the infusion had a significantly greater improvement in ‘off’ time, compared with those taking the placebo.

The reduction in ‘off’ time was achieved without an increase in dyskinesias and was reflected in the patients’ own assessment of the overall treatment effect.

The results were presented during the ‘Emerging Science’ session at the American Academy of Neurology (AAN) Annual Meeting in Boston, US, last month.

Professor Katzenschlager, lead investigator of the TOLEDO study, said: “TOLEDO provides the high-level evidence we needed for the efficacy and tolerability of apomorphine infusion in patients who are still experiencing debilitating treatment response fluctuations despite receiving optimised treatment, and confirms the clinical experience of those who have used apomorphine infusion for many years.”